YAP1 and glioblastoma: Importantly, tumor samples from 12 recurrent GBM patients treated with rQNestin34.5v.2 (ClinicalTrials.gov: NCT03152318) showed increased YAP1 expression in 7 patients (58.33%; P = 0.0020), underscoring the clinical relevance of YAP1 upregulation in response to oHSV therapy (Fig. 5G).33 YAP1 expression is similarly deleterious in BCBM, where enhanced expression increases the probability of brain metastasis in the TCGA-BRCA cohort (Fig. S15).